KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma.

Keri Toner, Lindsay A Renfro, Hema Dave, Gloria Pezzella, Qinglin Pei, Lisa Giulino-Roth, Terzah Horton, Frank G Keller, Kara M Kelly, Sharon M Castellino, Catherine M Bollard

Blood Adv 10(1) 183-191

PMID40990939
PMCIDPMC12805261
DOI10.1182/bloodadvances.2025016797
发表日期2025-09-24
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:森林图/亚组分析图;Figure 4.:森林图/亚组分析图。
摘要

摘要

There is an unmet need to examine antitumor immune responses and predictive biomarkers in the peripheral blood to guide effective combination immunotherapies in classical Hodgkin lymphoma (cHL). We sought to evaluate T-cell specific immune responses as well as cytokine and chemokine profiles including levels of soluble CD30 (sCD30), sCD163, and thymus and activation-regulated chemokine (TARC) in relation to event-free survival in patients with cHL. The Children's Oncology Group (COG) clinical trial AHOD1331 was a randomized phase 3 trial for patients with newly diagnosed high-risk cHL, aged 2 to 21 years, which compared standard chemotherapy and doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) with brentuximab vedotin (Bv) and AVE-PC with response adapted radiation. Our results demonstrate that chemotherapy with or without addition of anti-CD30 antibody-drug conjugate Bv is associated with a favorable cytokine environment for cellular and immunotherapies. Treatment of cHL on both arms increased tumor antigen-specific T-cell responses and resulted in decreased levels of sCD30, sCD163, and TARC. We demonstrate that treatment of cHL on COG AHOD1331 produced an environment that favors antitumor immune response, which may aid in application of further cellular and immunotherapies targeting cHL. This trial was registered at www.ClinicalTrials.gov as #NCT02166463.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1.Tumor-specific T cell response in response to tumor antigens MAGE-A4, PRAME and Survivin. T cell specificity to MAGE-A4 , PRAME, and Survivin both at baseline and post-therapy across both treatment arms (A) as measured by ELISpot in IFNγ SFC/100,000 cells (total n =144 and 72 per treatment arm) and (B) split by treatment arms (but due to numbers, without statistical relevance).
非 KM Figure
Figure 2.sCD30, sCD163, and TARC measured at baseline (before) and after therapy. sCD30 (A), sCD163 (B), and TARC (C) measured by enzyme-linked immunosorbent assay at baseline and after therapy in both chemotherapy arm and chemotherapy with addition of Bv. ns, not significant.
非 KM Figure
Figure 3.Chemokine Pre-treatment values and EFS. Risk of EFS event as a function of pretreatment marker values for sCD30 (A), sCD163 (B), and TARC (C). HR, hazard ratio.
非 KM Figure
Figure 4.Change in chemokines and EFS. Risk of posttreatment EFS event as a function of marker change from before treatment to after treatment for sCD30 (A), sCD163 (B), and TARC (C). HR, hazard ratio.
非 KM Figure